Report cover image

T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 180 Pages
SKU # IRE18450905

Description

T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Global Forecast 2024-2030


The T-Cell Immunotherapy Market size was estimated at USD 6.81 billion in 2023 and expected to reach USD 7.74 billion in 2024, at a CAGR 14.12% to reach USD 17.17 billion by 2030.

Global T-Cell Immunotherapy Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the T-Cell Immunotherapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the T-Cell Immunotherapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Alaunos Therapeutics, Inc., Apac Biotech, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Cellectis SA, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Inc., Gilead Sciences, Inc., Green Cross Corporation, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Inc., LAVA Therapeutics N.V., Lyell Immunopharma, Inc., Neogene Therapeutics, Inc., NeoTX Therapeutics Ltd., Novartis AG, Oxford Vacmedix UK Limited, Poseida Therapeutics, Inc., TScan Therapeutics, Inc., and Xenetic Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the T-Cell Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Mechanism Of Action
Active Immunotherapy
Passive Immunotherapy
Product Class
Bispecific Antibodies
Cytokines
Monoclonal Antibodies
Oncolytic Virus Therapy
Type of Therapy
CAR-T
TCR
TIL
Indication
B-cell Malignancies
Liver Cancer
Prostate Cancer
Renal Cell Carcinoma
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the T-Cell Immunotherapy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the T-Cell Immunotherapy Market?
3. What are the technology trends and regulatory frameworks in the T-Cell Immunotherapy Market?
4. What is the market share of the leading vendors in the T-Cell Immunotherapy Market?
5. Which modes and strategic moves are suitable for entering the T-Cell Immunotherapy Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

180 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. T-Cell Immunotherapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Cancer and Autoimmune Diseases
5.1.1.2. Use of Cell-Based Targeted Therapies
5.1.1.3. Increasing R&D Supporting T-cell Immunotherapy
5.1.2. Restraints
5.1.2.1. High Cost of Treatment
5.1.3. Opportunities
5.1.3.1. Commercialisation and Funding by Pharmaceutical Companies
5.1.3.2. Attractiveness of Off-the-Shelf Therapies
5.1.4. Challenges
5.1.4.1. Neurologic Toxicities and Cytokine Release Syndrome
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. T-Cell Immunotherapy Market, by Mechanism Of Action
6.1. Introduction
6.2. Active Immunotherapy
6.3. Passive Immunotherapy
7. T-Cell Immunotherapy Market, by Product Class
7.1. Introduction
7.2. Bispecific Antibodies
7.3. Cytokines
7.4. Monoclonal Antibodies
7.5. Oncolytic Virus Therapy
8. T-Cell Immunotherapy Market, by Type of Therapy
8.1. Introduction
8.2. CAR-T
8.3. TCR
8.4. TIL
9. T-Cell Immunotherapy Market, by Indication
9.1. Introduction
9.2. B-cell Malignancies
9.3. Liver Cancer
9.4. Prostate Cancer
9.5. Renal Cell Carcinoma
10. Americas T-Cell Immunotherapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific T-Cell Immunotherapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa T-Cell Immunotherapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Adaptimmune Therapeutics PLC
14.1.2. Alaunos Therapeutics, Inc.
14.1.3. Apac Biotech
14.1.4. Atara Biotherapeutics, Inc.
14.1.5. Autolus Therapeutics PLC
14.1.6. bluebird bio, Inc.
14.1.7. Bristol-Myers Squibb Company
14.1.8. CARsgen Therapeutics Holdings Limited
14.1.9. Cellectis SA
14.1.10. Chimera Bioengineering
14.1.11. Dendreon Pharmaceuticals LLC
14.1.12. Eureka Therapeutics, Inc.
14.1.13. Gilead Sciences, Inc.
14.1.14. Green Cross Corporation
14.1.15. Innovative Cellular Therapeutics
14.1.16. Iovance Biotherapeutics, Inc.
14.1.17. LAVA Therapeutics N.V.
14.1.18. Lyell Immunopharma, Inc.
14.1.19. Neogene Therapeutics, Inc.
14.1.20. NeoTX Therapeutics Ltd.
14.1.21. Novartis AG
14.1.22. Oxford Vacmedix UK Limited
14.1.23. Poseida Therapeutics, Inc.
14.1.24. TScan Therapeutics, Inc.
14.1.25. Xenetic Biosciences, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. T-CELL IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 2. T-CELL IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. T-CELL IMMUNOTHERAPY MARKET DYNAMICS
FIGURE 7. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 8. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2023 VS 2030 (%)
FIGURE 10. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
FIGURE 12. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 14. T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us